Targeting BCL2-Proteins for the Treatment of Solid Tumours
Author:
Open Access
- 27 August 2014
- journal article
- review article
- Published by Wiley in Advances in Medicine
- Vol. 2014, 1-14
Abstract
Due to their central role in the regulation of apoptosis, the antiapoptotic BCL2-proteins are highly promising targets for the development of novel anticancer treatments. To this end, several strategies have been developed to inhibit BCL2,, BCL-w, and MCL1. While early clinical trials in haematological malignancies demonstrated exciting single-agent activity of BCL2-inhibitors, the response in solid tumours was limited, indicating that, in solid tumours, different strategies have to be developed in order to successfully treat patients with BCL2-inhibitors. In this review, the function of the different antiapoptotic BCL2-proteins and their role in solid tumours will be discussed. In addition, a comprehensive analysis of current small molecules targeting these antiapoptotic BCL2-proteins (e.g., ABT-737, ABT-263, ABT-199, TW-37, sabutoclax, obatoclax, and MIM1) will be provided including a discussion of the results of any clinical trials. This analysis will summarise the potential of BCL2-inhibitors for the treatment of solid tumours and will unravel novel approaches to utilise these inhibitors in clinical applications.
Keywords
This publication has 146 references indexed in Scilit:
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 DependencyCancer Cell, 2012
- A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerBritish Journal of Cancer, 2012
- BCL2A1: the underdog in the BCL2 familyCell Death & Differentiation, 2011
- BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family ProteinsJournal of Medicinal Chemistry, 2010
- A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignanciesCancer Chemotherapy and Pharmacology, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Apogossypol Derivatives as Pan-Active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family ProteinsJournal of Medicinal Chemistry, 2009
- How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?Trends in Cell Biology, 2008
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- The Hallmarks of CancerCell, 2000